Applications of CA125 in Ovarian Cancer
DOI:
https://doi.org/10.54097/jhenwt17Keywords:
Ovarian cancer; CA125; cancer immunotherapies.Abstract
Ovarian cancer is currently the most fatal among gynecological malignancies with a low survival rate, especially in the case of type II tumors. Cancer antigen 125, the primary protein biomarker associated with ovarian cancer, has been researched for its involvement in the ovarian cancer pathogenesis and its potential applications in enhancing both accurate diagnostics and effective therapies. Research has investigated the connections between CA125 and several biological pathways, revealing their associations with cancer cell proliferation and migration. Further research aims to utilize CA125 for a more accurate diagnosis and potential treatments for ovarian cancer. Approaches have been established to address the low specificity of CA125 diagnostic tests, including altering the traditional CA125 value threshold used for ovarian cancer diagnosis and detecting CA125 alongside other antigens. CA125-specific cancer vaccines and immunotherapies are currently undergoing clinical trials and are being developed for future clinical use.
Downloads
References
National Cancer Institute. (n.d.). Cancer of the ovary - cancer stat facts. SEER.
Yuan, Q. et al. The effect of CA125 on metastasis of ovarian cancer: Old marker new function. Oncotarget, 2017, 8(30), 50015–50022.
Gubbels, J. A. et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Molecular Cancer, 2010, 9(1), 11.
Liu, Q. et al. C-terminus of MUC16 activates Wnt signaling pathway through its interaction with β-catenin to promote tumorigenesis and metastasis. Oncotarget, 2016, 7(24), 36800–36813.
Zhang, R. et al. Molecular Biomarkers for the Early Detection of Ovarian Cancer. International Journal of Molecular Sciences, 2022, 23(19), 12041.
van der Burg, M. E. L. et al. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Annals of Oncology, 1990, 1(4), 301–302.
Barbieri, R. L. et al. Elevated serum concentrations of CA-125 in patients with advanced endometriosis. Fertility and Sterility, 1986, 45(5), 630–634.
Van Calster, B. et al. A Novel Approach to Predict the Likelihood of Specific Ovarian Tumor Pathology Based on Serum CA-125: A Multicenter Observational Study. Cancer Epidemiology, Biomarkers & Prevention, 2011, 20(11), 2420–2428.
Al Musalhi, K. et al. Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the Preoperative Assessment of Patients with Adnexal Mass. Oman Medical Journal, 2016, 31(5), 336–344.
Wang, Y.-S. et al. CA125-Tn ELISA assay improves specificity of pre-operative diagnosis of ovarian cancer among patients with elevated serum CA125 levels. Annals of Translational Medicine, 2021, 9(9), 788.
Reinartz, S. et al. Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines--a preliminary report. Hybridoma, 1999, 18(1), 41–45.
Reinartz, S. et al. Vaccination of Patients with Advanced Ovarian Carcinoma with the Anti-Idiotype ACA125: Immunological Response and Survival (Phase Ib/II). Clinical Cancer Research, 2004, 10, 1580-1587.
Sabbatini, P. et al. Phase I Study of Abagovomab in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Clinical Cancer Research, 2006, 12(18), 5503–5510.
Noujaim, A. A. et al. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. Cancer biotherapy & radiopharmaceuticals, 2001, 16(3), 187–203.
Brewer, M. et al. Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study. Gynecologic Oncology, 2020, 156(3), 523–529.
Banville, A. C. et al. Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer. Gynecologic Oncology, 2021, 160(2), 520–529.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
